Evelyn Matta Fontanet, MD
Internal Medicine · Rio Grande, PRNPI 1700822574
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.2%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Johnson & Johnson at 36.9% of the total. Reporting peaked in 2019 at $2,621 and has fallen 88.1% since, to $313 in 2025. Among internal medicine clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 173 payments — averaging $43.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$3K
- E.r. Squibb & Sons, L.L.C.$1K
- Boehringer Ingelheim$807
- Sanofi-aventis U.S. LLC$483
- PBG Puerto Rico LLC$444
- Merck$429
- plus $1K from 12 others
Across 14 payments — averaging $13,755 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$177K
- AbbVie$8K
- AstraZeneca$8K
What the payments were for
- Consulting fees$3,39045%
- Speaking & faculty fees$2003%
- Travel & lodging$190%
- Food & beverage$3,85651%
- Education$60%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 23 | $2,780 |
| E.r. Squibb & Sons, L.L.C. | 16 | $1,461 |
| Boehringer Ingelheim | 29 | $807 |
| Sanofi-aventis U.S. LLC | 16 | $483 |
| PBG Puerto Rico LLC | 25 | $444 |
| Merck | 10 | $429 |
| Novo Nordisk | 12 | $285 |
| AstraZeneca | 16 | $274 |
| Amgen | 9 | $193 |
| Pfizer Pharmaceuticals LLC | 5 | $64 |
| Sanofi | 2 | $63 |
| Mannkind Corporation | 1 | $59 |
| Eli Lilly Export S.A. Puerto Rico Branch | 2 | $50 |
| AbbVie | 2 | $43 |
| GSK | 2 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Abbott | 1 | $22 |
| Dexcom, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$2,290
- SOTAGLIFLOZIN$200
How this compares
$7,531 in reported general payments places this provider in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 592 | $413,422 |
| EliquisApixaban | 344 | $240,345 |
| XareltoRivaroxaban | 223 | $155,059 |
| JardianceEmpagliflozin | 211 | $150,313 |
| JanumetSitagliptin Phos/Metformin Hcl | 210 | $145,257 |
| JanuviaSitagliptin Phosphate | 137 | $101,055 |
| Candesartan Cilexetil | 1,355 | $94,100 |
| SynthroidLevothyroxine Sodium | 1,324 | $88,027 |
| OzempicSemaglutide | 65 | $75,586 |
| LantusInsulin Glargine,hum.Rec.Anlog | 652 | $73,822 |
| TrulicityDulaglutide | 61 | $72,762 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 115 | $71,453 |
| TradjentaLinagliptin | 95 | $67,812 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 91 | $61,141 |
| ProliaDenosumab | 21 | $37,238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $274 | $428,867624 claims |
| MerckJanumet, Januvia, Janumet Xr | $429 | $317,766462 claims |
| Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr, Jentadueto, Glyxambi | $807 | $313,587456 claims |
| Johnson & JohnsonXarelto | $2,780 | $155,059223 claims |
| AbbVieSynthroid, Lumigan | $43 | $110,0251,399 claims |
| Novo NordiskOzempic | $285 | $75,58665 claims |
| Sanofi-aventis U.S. LLCLantus | $483 | $73,822652 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $29 | $46,80179 claims |
| AmgenProlia | $193 | $37,23821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.
Other internal medicine in Rio Grande
- Nelson VallejoLas Piedras$621K
- Ricardo FernandezSan Juan$351K
- Ronald Collazo PaganManati$206K
- Angel VinuelaDorado$182K
- Julio JimenezSan Lorenzo$99K
- Luis Negron GarciaSan German$24K
- Jorge Torres OlmedaCoto Laurel$23K
- Norma SalgadoSan Juan$21K
- Victor Gordo GonzalezSan Juan$21K
- Luis Rivera ColonRio Piedras$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.